Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

7503 Background: Optimal initial therapy for mantle cell lymphoma (MCL) remains uncertain. The randomized phase 2 NCTN trial E1411 tested if progression-free survival (PFS) is prolonged by addition of bortezomib (V) (1.6 mg/m2 SC/IV days 1, 8) to bendamustine-rituximab (BVR vs BR) induction and/or by addition of lenalidomide (L) to rituximab (LR vs R) consolidation. Here we report efficacy and...

  • BVR was not better than BR for MCL induction in the phase II ECOG-ACRIN E1411 trial. Median PFS was 64.1 v 64 months.